Programs that provide the Shingrix (recombinant zoster vaccine, or RZV) inoculations which prevent recipients from contracting shingles (herpes zoster). The vaccine is recommended for adults age 50 and older without contraindications, and adults 19 years and older who are immunocompromised. It is administered in a two dose schedule separated by two to six months. The vaccine cannot be used to treat the disease or post-herpetic neuralgia (pain after the rash is gone) once it develops, but can prevent future occurrences. The previously approved and used Zostavax vaccine is no longer available for use in the United States.